Compare FSUN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | ESPR |
|---|---|---|
| Founded | 1892 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.0M | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | FSUN | ESPR |
|---|---|---|
| Price | $38.36 | $4.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $46.33 | $6.67 |
| AVG Volume (30 Days) | 138.6K | ★ 5.3M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.52 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $384,497,000.00 | $303,802,000.00 |
| Revenue This Year | $19.09 | $26.11 |
| Revenue Next Year | $62.50 | N/A |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | ★ 10.48 | 2.83 |
| 52 Week Low | $29.95 | $0.69 |
| 52 Week High | $45.32 | $4.13 |
| Indicator | FSUN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 61.22 |
| Support Level | $37.13 | $3.87 |
| Resistance Level | $40.07 | $4.13 |
| Average True Range (ATR) | 1.06 | 0.20 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 64.32 | 79.00 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.